Autonomous cortisol secretion is a disorder caused by excessive cortisol production from a benign tumour of the adrenal gland. Credit: SciPro / Shutterstock.com.

Sparrow Pharmaceuticals has dosed the first subject in the Phase II ACSpire clinical trial of SPI-62 to treat autonomous cortisol secretion (ACS).

ACS is a condition caused by excessive cortisol production from a benign tumour of the adrenal gland.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The long-term, open-label trial is designed to assess the safety, efficacy, and pharmacological effects of SPI-62 in subjects with hypercortisolism linked to a benign adrenal tumour.

In addition, the impact of SPI-62 on hypercortisolism morbidities, including diabetes or impaired glucose tolerance, hyperlipidemia, hypertension, and osteopenia, will also be evaluated.

The trial is enrolling up to 30 subjects at study centres in the US, with sites in Romania, France, and the UK to be added in the future.

SPI-62 is a selective inhibitor of HSD-1.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ACSpire will complement the Phase II RESCUE study that is currently underway to treat ACTH-dependent Cushing’s syndrome.

Sparrow Pharmaceuticals chief medical officer Frank Czerwiec said: “ACS is a dangerous condition, with high morbidity and risk of death, with patients often having unexplained metabolic disease, cardiovascular disease, or osteopenia, and experiencing a 35% higher rate of mortality over a five-year span.

“However, most patients don’t even know they have ACS and are only diagnosed after an appropriate endocrine workup following the discovery of an adrenal tumour on a CT or MRI scan for unrelated reasons.

“SPI-62 could represent the first treatment to be approved for this large yet underappreciated and underserved patient population.”